PF-Atlas › Clinical Trials › NCT07643038

Treatment Strategy for Patients With RA-ILD

Tocilizumab · Phase 4

Registry ID

NCT07643038

Phase

Phase 4

Status

Not yet recruiting

Drug / intervention

Tocilizumab

Sponsor

Chinese SLE Treatment And Research Group

Start

2026-07-01

Enrollment

204

Locations

About this trial

This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, telitacicept, and csDMARD methotrexate in patients with RA-ILD.

View NCT07643038 on ClinicalTrials.gov →

Explore related

All Tocilizumab trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT07643038 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.